The Health Pulse
🎙️ The Health Pulse – Your quick guide to better health!
In under 20 minutes, get expert insights on health and nutrition. Stay informed, and take charge of your wellness with actionable tips. Whether optimizing your health or exploring diagnostics, we keep it simple and insightful.
Listen, learn, and take control—one pulse at a time! 🔬✨
The Health Pulse
Episode 145 | What ApoB Alone Can't Tell You
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
ApoB has transformed how we think about cardiovascular risk because it measures something LDL cholesterol cannot: the number of atherogenic lipoprotein particles circulating in your blood. But once you know the particle count, another question emerges—are all ApoB-containing particles biologically equivalent?
In this episode of The Health Pulse, we go beyond the standard cholesterol panel to explore the major families of ApoB-containing lipoproteins, including LDL, triglyceride-rich lipoproteins and their remnants, and lipoprotein(a), or Lp(a). Each carries ApoB, but their composition, metabolism, and biological effects can differ substantially.
We begin with the fundamental distinction between cholesterol mass and particle number. LDL-C measures how much cholesterol is being transported within LDL particles, while ApoB provides an estimate of the total number of circulating atherogenic particles. When those measurements become discordant—particularly in people with insulin resistance, elevated triglycerides, or metabolic syndrome—LDL-C alone can underestimate the particle burden.
Then we examine Lp(a), a largely genetically determined particle consisting of an LDL-like core attached to apolipoprotein(a). Its distinctive kringle structures and ability to carry oxidized phospholipids may contribute additional inflammatory and vascular effects beyond its cholesterol content, helping explain its association with atherosclerotic cardiovascular disease and calcific aortic valve disease.
On the metabolic side, we explore triglyceride-rich lipoproteins and remnant particles. Insulin resistance can increase hepatic VLDL production while disrupting normal triglyceride handling and particle clearance. The result can be a large burden of ApoB-containing remnants even when conventional LDL-C appears reassuring.
We then dive into a large European Heart Journal analysis that profiled 2,918 circulating proteins to examine the biological pathways associated with different ApoB-containing lipoproteins. Using UK Biobank data with external replication in MESA, researchers found striking differences in the protein signatures associated with LDL, triglyceride-rich lipoproteins, and Lp(a). Triglyceride-rich particles were associated with hundreds of proteins involving immune activation and vascular remodeling, suggesting that the biology surrounding atherogenic particles may provide additional information beyond simply counting them.
These findings don't make ApoB less important. Instead, they add another layer: atherosclerotic risk reflects both the opportunity for ApoB particles to enter the arterial wall and the biological characteristics of the particles and metabolic environment surrounding them.
Finally, we translate the science into a practical testing strategy. We discuss ApoB alongside the standard lipid panel, direct Lp(a) measurement, fasting insulin, HbA1c, triglyceride-to-HDL ratio, and hs-CRP. We also explain why Lp(a) results reported in mg/dL and nmol/L should not be converted using a universal fixed formula, because particle composition varies between individuals.
If your cardiovascular risk assessment still begins and ends with LDL-C, this episode will show you what may be hiding behind that single cholesterol number—and why understanding the particles carrying cholesterol can reveal a much deeper cardiovascular story
📞 Need lab work done from the comfort of home? QLM offers fast, reliable mobile phlebotomy services—no clinic visit required.
📅 Book your appointment or learn more at:
👉 Quick Lab Mobile
📧 Contact us: info@quicklabmobile.com
💬 Enjoyed the episode? Leave us a review and let us know what topics you'd like us to cover next! Your feedback helps us bring you the content that matters most.
Disclaimer: The information provided in this podcast is for informational purposes only and should not be considered medical advice. The content discussed is based on research, expert insights, and reputable sources, but it does not replace professional medical consultation, diagnosis, or treatment. We strive to present accurate and up-to-date information, medical research is constantly evolving. Listeners should always verify details with trusted health organizations, before making any health-related decisions. If you are experiencing a medical emergency, such as severe pain, difficulty breathing, or other urgent symptoms, call your local emergency services immediately. By listening to this podcast, you acknowledge that The Health Pulse and its creators are not responsible for any actions taken based on the content of this episode. Your health and well-being should always be guided by the advice of qualified medical professionals.
Welcome And The Big Question
NicoletteWelcome to the Health Pulse, your go-to source for quick, actionable insights on health, wellness, and diagnostics. Whether you're looking to optimize your well-being or stay informed about the latest in-medical testing, we've got you covered. Join us as we break down key health topics in just minutes. Let's dive in.
MarkWhat
Why ApoB Beats LDL Cholesterol
Markif uh what if the standard cholesterol test you get every single year at your doctor's office is, you know, completely missing the actual biological triggers of heart disease?
RachelYeah. It's a scary thought.
MarkRight. I mean, welcome to the deep dive. We are taking a really hard look at cardiovascular risk today.
RachelYeah.
MarkAnd if you follow this space, you probably already know that the old paradigm of like good and bad cholesterol is pretty much dead.
RachelCompletely dead, yeah.
MarkToday, a marker called APOB is the undisputed gold standard for measuring your risk. But we're looking at a brand new article from Quick Lab Mobile, and it breaks down this massive study just published in the European Heart Journal. It's a huge study. It really is. And the mission for our deep dive today is to answer a very specific and honestly somewhat unsettling question. Are all APOB particles equally dangerous?
RachelBecause the new data suggests they really aren't.
MarkExactly. Simply counting the number of these particles in your blood is it's barely scratching the surface. So, okay, let's unpack this.
RachelAaron Powell Right. So to really understand what this European Heart Journal study reveals, we kind of have to establish what APOB is actually doing in the first place.
MarkAaron Powell Right. Set the baseline for us.
RachelYeah. So APOB or APOLIPO protein B is basically a structural protein. Every single athrogenic lipoprotein particle in your blood.
MarkAaron Powell Meaning the ones capable of causing black, right?
RachelExactly. The ones that cause the damage. Every single one of them carries exactly one APOB molecule. So when you get an APOB test, you aren't measuring the volume or like the mass of cholesterol in your blood.
SPEAKER_02You're getting a headcount.
RachelYes, precisely. You are getting a precise one-to-one headcount of the individual particles that actually have the potential to penetrate your arterial wall. That is exactly why it's the gold standard.
SPEAKER_02Aaron Powell But this new research kind of pushes this past the headcount, doesn't it?
RachelAaron Powell It does. It forces us to ask, you know, what are these particles actually structurally composed of? And more importantly, what biological chaos do they unleash once they actually breach the vessel wall?
MarkAaron Powell So to conceptualize this for you listening, think of your bloodstream like a highway, right? Old school LDL testing just weighs all the cargo on the road.
RachelAaron Powell Right, just total mass.
MarkAaron Powell But measuring APO B is actually counting the number of delivery trucks that could potentially crash into the arterial wall. Is that right?
RachelAaron Ross Powell That is a much more accurate way to view it. The badge or the truck gets them in the door, but the biological payload dictates the actual damage. Aaron Powell Right.
MarkAnd so if APOB counts the trucks, we need to know what kinds of trucks are actually on the road. And the source categorizes these trespassers into three distinct
Three ApoB Particle Families
Markstructural families, right?
RachelAaron Powell Yeah, exactly. Three. So you have particles originating from your intestines, which are called chylomicrons, and they carry a shorter APOB38 badge.
MarkOkay, so that's the gut.
RachelRight. But in a fasting state, which is one we usually test, your blood is dominated by the liver-derived particles. And all of these carry the full-length APOB100 badge.
MarkAaron Powell Okay, so ApoB100 is from the liver.
RachelAaron Powell Exactly. And this includes very low density lipoproteins, or VLDL. It includes intermediate density lipoproteins, or IDL, standard LDL, of course, and a very specific genetic variant called LPA.
MarkAaron Powell Right. Those liver-derived ones are the main focus of this study. And the first family is just standard LDL, which as I understand it is actually just the end product of a life cycle, right? Aaron Ross Powell, Jr.
RachelIt is, yeah. The liver packs triglycerides and cholesterol into this massive VLDL particle, basically to deliver energy to your tissues. Trevor Burrus, Jr.
MarkIt's like a really full cargo truck.
RachelExactly. And as that VLDL travels through your circulation, it drops off its fat cargo, it shrinks down into an IDL particle, and eventually it metabolizes all the way down into a standard LDL particle.
MarkAaron Powell Which brings us to the second family, which is the triglyceride-rich lipoproteins. This includes that newly minted VLDL we just mentioned, but the article focuses heavily on something called remnants.
RachelOh, remnants are incredibly insidious.
MarkWhy is that?
RachelWell, as a VLDL particle drops off its triglycerides, it's supposed to just be cleared from the bloodstream, right? But when clearance is impaired, you are left with these partially depleted, highly condensed particles.
MarkSo they're smaller.
RachelThey're smaller than VLDL, yeah. Meaning they easily slip past the endothelial barrier of your artery, but they are incredibly rich in cholesterol.
MarkOkay, I definitely want to come back to why those remnants are so dangerous in a minute. But I want to look at the third family first, which
Lp(a) Genetics And Inflammation
Markis LPA.
RachelRight.
MarkThe article emphasizes that this one is driven almost entirely by genetics.
RachelAlmost 100%, yes.
MarkSo if you are listening to this right now and you eat perfectly, you exercise daily, you sleep eight hours a night, could you still have a highly elevated risk from LPA?
RachelWithout a doubt. You absolutely could. And what's fascinating here is the sheer molecular stubbornness of LPA.
MarkStubbornness. What do you mean by that?
RachelWell, it starts with a standard LDL core, right? Complete with that ACO B100 access badge we talked about. But it has an entirely separate massive protein structure attached to it. It's called apolepoprotein.
MarkOkay, so it's LDL with an attachment.
RachelYeah, and this isn't just loosely associated. It is bound to the LDL core by a rigid disulfide bond.
MarkWow, so it's locked on there.
RachelExactly. That chemical sulfur bridge makes LPA incredibly stable and highly resistant to being broken down or cleared by your normal liver receptors.
MarkThe source also mentions Kringle structures on this attached protein weight. Kringle like like the pastry?
RachelYes, literally like the pastry.
MarkReally? What does that actually look like on a molecular level and why does the number of them matter?
RachelSo it's named after the Danish pastry because the amino acid sequences literally loop back on themselves in a way that resembles a pretzel or a Kringle under a microscope.
MarkThat's wild.
RachelIt is. But structurally, these loops act like biological velcro.
MarkOh wow.
RachelYeah. Based on your specific LPA gene, you inherit a certain number of these Kringle repeats. Some people have very few, some have many, but these sticky loops are precisely why LPA binds to the damaged arterial wall so aggressively.
MarkAaron Powell But it's not just getting stuck that makes it dangerous, right? Because the paper node's LPA brings something else into the artery wall with it.
RachelYes, it brings oxidized phospholipids.
MarkWhich are what, exactly?
RachelThey are these degraded, highly reactive fat molecules that act as a massive irritant to your tissue. So when LPA crashes into the vessel wall, it doesn't just deposit cholesterol, it unleashes these oxidized phospholipids.
MarkThey're dropping a bomb.
RachelBasically, yeah, and that directly provokes the immune system. This intense localized inflammation is exactly why LPA is a primary driver not just of coronary artery disease, but of calcific aortic valve disease.
MarkWait, it affects the heart valves too.
RachelOh, absolutely. The tissue gets so inflamed that the body tries to heal it by depositing calcium, which essentially turns a flexible heart valve into rigid bone.
MarkAaron Powell That is terrifying.
RachelIt really is.
MarkOkay, so LPA is this genetically determined, heavily armed trespass. And we can't currently diet our way out of that one.
RachelRight. Sadly not.
Insulin Resistance And Remnant Particles
MarkBut let's look at the second family, the triglyceride remnants, because we can heavily influence those through metabolic health, right?
RachelAaron Ross Powell Oh, absolutely. We have a lot of control there.
MarkAaron Powell Because the source draws this massive straight line between insulin resistance and these remnant particles. Biologically speaking, why does my body's inability to handle carbohydrates suddenly flood my bloodstream with cholesterol remnants?
RachelWell, because we tend to think of insulin solely as a blood sugar regulator, right? But its role in lipid metabolism is honestly just as critical.
SPEAKER_02How so?
RachelSo in your adipose tissue, your fat cells, insulin acts as a molecular lock. It suppresses lipolysis, basically telling your fat cells to hold on to their stored energy.
MarkOkay, it makes sense.
RachelBut as you become insulin resistant, your cells become deaf to that signal. The lock breaks.
MarkSo the fat cells just start leaking.
RachelExactly. They hemorrhage free fatty acids directly into your circulation, and all those free fatty acids head straight to the liver.
MarkSo the liver is just getting bombarded.
RachelYes. It's suddenly overwhelmed with this massive influx of energy, so it panics and it aggressively repackages those fatty acids into triglycerides, shoves them inside VLDL particles, and pumps them back into the blood. And at the exact same time, insulin resistance alters hepatic glucose metabolism, forcing the liver to create even more new fat from scratch.
MarkSo you've got this massive fleet of VLDL particles just flooding the bloodstream. Yeah. But how did they become the dangerous remnants we talked about earlier?
RachelRight. So that comes down to clearance. As these VLDL particles circulate, there's an enzyme on the lining of your blood vessels called lipoprotein lipase. It's supposed to grab them and unload the triglycerides into your muscles and tissues.
MarkBut insulin resistance messes that up.
RachelIt impairs that enzyme, yes. It gets sluggish.
MarkRight.
RachelFurthermore, these particles carry surface proteins. Think of them as molecular barcodes like APOS C3 and APOE.
SPEAKER_02No cat codes.
RachelRight. And in an insulin-resistant environment, you get an over-expression of APOS C3, which essentially hides the particle from the liver's clearance receptors.
MarkBut the normal metabolic machinery completely breaks down.
RachelCompletely.
MarkThe triglycerides are only partially unloaded, the liver can't clear them, and you're just left with this swarm of small, highly concentrated remnant particles.
RachelYes. And this severely distorts your standard lipid panel. You develop high triglycerides and low HDL, but your standard LDLC mass might actually look perfectly normal.
MarkHold on, I really want to underline this for the listener. You could get your annual lab results back, right? And your doctor says your LDLC is in the safe zone, but underneath, you are actually harboring a massive concentration of these tiny cholesterol depleted remnant particles.
RachelYes. That happens all the time.
MarkThat's crazy.
RachelIt's because the total volume of cholesterol inside the particles might be low, making your LDLC mass look acceptable. But the APUB B head count, the actual number of particles capable of breaching the arterial wall is wildly elevated.
MarkRight, because there's just so many of these little remnants.
RachelExactly. And because these remnants are prone to oxidation and they carry their own inflammatory barcode proteins, your actual cardiovascular risk is severely underestimated by those standard tests.
The Proteomic Fingerprints Study
MarkWhich perfectly bridges us to the actual European Heart Journal study. We know these three families, LDL, LPA, and triglyceride remnants. We know they're structurally different. Right. But the researchers didn't want to just look at their physical shapes. They wanted to see the chemical trail they leave in the blood.
RachelThe biological environment.
MarkYeah. So they analyzed over 35,000 participants in the UK Biobank, and then they validated it in another 5,900 people from the multi-ethnic study of atherosclerosis. But they weren't measuring cholesterol, right? They were measuring, what was it, 2,918 different plasma proteins.
RachelYeah, almost 3,000 proteins. It was an unprecedented look at the biological environment. They were searching for the proteomic fingerprint of each particle family.
MarkLike what alarms are they setting off?
RachelExactly. If these particles are causing damage, what systemic alarms are they tripping in the body?
MarkHere's where it gets really interesting. The disparity in the result is shocking. When they isolated standard LDL, it was significantly associated with only 30 proteins. So 30. Right. LPA was associated with 53 proteins. But the triglyceride-rich lipoproteins, they were associated with 471 different proteins.
RachelYeah, the magnitude of that difference, I mean, it cannot be overstated. A 471 protein signature means that triglyceride remnants aren't just passively floating in the blood, you know.
MarkThey're doing something.
RachelThey are actively engaging with the immune system and the vascular tissue.
MarkAnd the study highlights a significant overlap, right? Because the triglyceride remnants and the LPA particles shared 36 specific proteins. What are those proteins actually doing?
RachelRight. So those 36 are heavily enriched in pathways driving immune activation and vascular remodeling.
MarkVascular remodeling. That sounds bad.
RachelIt is. When we say vascular remodeling, we mean the structural cells of your blood vessels, the smooth muscle cells. They are chemically instructed to change their shape, to multiply, and lay down fibrous tissue.
MarkBasically making the artery stiffer.
RachelExactly. And the immune activation is largely driven by chemokines, which act as a distress beacon, calling in macrophages.
MarkThe immune system's cleanup crew.
RachelRight. But these macrophages dive into the arterial wall, they gorge themselves on the oxidized lipids from the remnants and the LPA, and they become what we call foam cells.
MarkAaron Powell And those form the plaque, right?
RachelExactly. They form the necrotic core of a plaque.
MarkSo these particles are effectively orchestrating their own plaque buildup by weaponizing the body's immune response.
RachelAaron Powell That's a great way to put it. Yeah.
MarkAnd the researchers use something called mediation modeling to quantify this, didn't they? Can you explain what mediation modeling actually does here?
RachelYeah. So mediation modeling is a statistical method used to trace the chain of causality.
NicoletteOkay.
RachelRather than just saying, you know, high remnants equal heart attacks, mediation modeling asks how much of that heart attack risk mathematically passes through these specific inflammatory proteins.
MarkGot it. And what do they find?
RachelThe findings were profound. They estimated that about 14% of the coronary risk from LPA is mediated by these proteomic alterations.
MarkOkay, 14%.
RachelBut for the triglyceride-rich remnants, a staggering 62% of their coronary risk is mediated by these inflammatory and immune proteins.
Mark62%.
RachelYeah.
MarkThat implies the vast majority of the danger for metabolic dysfunction isn't just the cholesterol itself, it's the massive biological fire it starts in the bloodstream.
RachelExactly.
LDL As The Silent Killer
MarkBut wait, I have to push back on the LDL data for a second. If LDL only triggered 30 proteins, and the study noted its protein score wasn't independently associated with coronary events after adjustments. I mean, have we been wrong this whole time? Are you saying plain old LDL is effectively harmless?
RachelOkay, so if we connect this to the bigger picture, it is absolutely vital that we don't draw that conclusion.
SPEAKER_02Okay, good.
RachelLDL is absolutely lethal, but its mechanism of lethality is different. The lack of a massive proteomic signature simply means LDL is a silent killer.
MarkExplain that. If it's lethal, why isn't the body sounding the alarm?
RachelAaron Powell Because standard LDL mostly exerts its harm through a slow, cumulative, localized physical process.
MarkLike it just builds up over time.
RachelRight. It slips into the artery wall and gets retained. It doesn't carry the highly reactive oxidized phospholipids of LPA, and it doesn't carry the inflammatory EPOS-3 surface proteins of the triglyceride remnants. So it doesn't trigger 471 systemic alarms in your circulating plasma. But over decades, that localized physical accumulation builds plaque, it narrows the artery, and eventually it ruptures.
MarkSo LDL operates under the radar while the other two are screaming through a megaphone.
RachelExactly. But all three end in cardiovascular events.
MarkThat clarifies a massive potential misunderstanding. So moving
A Smarter Testing Stack
Markfrom this incredibly detailed biology into practical application, how do you, the listener, actually use this to assess your own health? If APOW is the ultimate headcount, how do we capture both the number of trespassers and the biological weapons they're carrying?
RachelWell, you have to build a comprehensive testing stack. First off, you do not abandon APOB. APOB remains the absolute best metric to define your exposion opportunity.
MarkRight, the head count.
RachelIt tells you exactly how many particles are capable of entering the arterial wall, but you must contextualize that number.
MarkAaron Powell So what exactly is in this stack?
RachelYou start with a standard lipid panel, you know, LDLC, triglycerides, HDLC. From there, your physician can calculate your non-HDL cholesterol, which basically encompasses the cholesterol mass of all APOB particles.
SPEAKER_02Got it.
RachelThey can also estimate your remnant cholesterol, giving you a real sense of the burden from those triglyceride-rich particles.
MarkAnd what about LPA? Can we just deduce that from the APOB count?
RachelNo. And this is a critical clinical trap.
MarkReally?
RachelYeah. Two patients could have an identical APOB score of 90, right? One might have virtually zero LPA, while the other has a massive genetically driven concentration that fundamentally changes their risk profile and their treatment timeline.
MarkOh wow. So you have to measure it separately.
RachelLPA must be measured directly via a specific blood test. And for the listener looking at their labs, notice if your LPA is reported in milligrams per deciliter, which measures mass, or nanomoles per liter, which measures particle count.
MarkCan't you just use a math formula to convert one to the other?
RachelYou mathematically cannot.
MarkWait, really? Why not?
RachelBecause, as we discussed, the isoform, the physical structure of the LPA particle, varies wildly from person to person based on how many of those Kringle loops they inherited?
MarkRight, the Velcro loops.
RachelExactly. You can't use a universal conversion factor because you'd be assuming everyone's LPA molecule weighs exactly the same, which is genetically false.
MarkGood to know. So what does this all mean for our metabolic context? If I have my APOB, my standard panel, and my LPA direct measurement, is the picture complete?
RachelNot if you want to understand if you are fueling that 471 protein fire we talked about. You have to measure the metabolic environment. That means testing fasting insulin, not just fasting glucose. You need your HBA1C, a look at your triglyceride to HDL ratio to assess insulin sensitivity.
MarkAnd inflammation markers, too.
RachelIdeally, yes. An inflammatory marker like HSCRP to see if your body is already in a state of systemic immune distress.
MarkThis raises an important question, though, doesn't it? Like as medicine evolves, are we just treating a lipid number on a lab report, or do we have to start treating the entire biological environment of the patient?
RachelWell, that is the exact paradigm shift the European heart journal study represents. You do not have to choose between managing the particle number and managing the particle biology. A neat bowl. Exactly. APOB establishes the baseline opportunity for disease. But the specific particle type, be it an oxidized LPA particle or a metabolically deranged triglyceride remnant, along with the surrounding metabolic dysfunction, dictates exactly how that exposure accelerates into physical heart disease.
MarkSo to synthesize this entire journey for you today, APOW B is undeniably the ultimate headcount of the dangerous particles in your blood. But knowing exactly who is in that crowd, you know, whether it's genetically engineered LPA armed with oxidized phospholipids, or metabolically driven triglyceride remnants weaponizing your immune system, that's the key to understanding your true risk.
RachelThat's spot on.
MarkIt is not just about the number of access badges, it is about what those particles are chemically programmed to do once they breach the arterial wall.
RachelThe precision of the science is staggering, really, and it allows us to move away from guesswork and directly target the root biological mechanisms
The Future Of Personalized Prevention
Rachelof risk.
MarkWhich leaves me with a final, somewhat provocative thought for you to explore on your own. If LPA is purely genetic and stubbornly ignores lifestyle changes, and triglyceride remnants are heavily tied to insulin resistance and how your specific body handles carbohydrates, are we rapidly approaching a future where a generalized heart-healthy diet is completely obsolete?
RachelThat's a great question. Right.
MarkLike if we can identify your unique proteomic fingerprint, will we soon be treating cardiovascular risk by manipulating individual immune proteins and pathways, essentially stopping heart disease years before a plaque even has the physiological chance to form?
RachelThat is exactly the frontier of preventative cardiology.
MarkIt really makes the old binary view of cholesterol look incredibly primitive. The murky waters of cardiovascular diagnostics are finally starting to clear. Thank you so much for joining us on this deep dive. Keep questioning the consensus, keep looking past the standard lipid panel, and keep seeking out the why behind your health.
NicoletteWe'll see you next time.quickLabmobile.com. Stay informed, stay healthy, and we'll catch you in the next episode.
Podcasts we love
Check out these other fine podcasts recommended by us, not an algorithm.
